Impact of tenofovir vs. entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study
The comparative effectiveness of tenofovir <i>vs.</i> entecavir treatment in preventing hepatocellular carcinoma (HCC) for patients with chronic hepatitis B (CHB) remains controversial. Using a nationwide cohort study involving 55,885 patients to investigate CHB as a multi-state disease over 13 years, we show that tenofovir (<i>vs.</i> entecavir) treatment is associated with lower risks of HCC, hepatic decompensation, and a composite endpoint of adverse liver-related outcomes (hepatic decompensation, HCC, and liver-related deaths), regardless of age, sex, diabetes, alcohol-related disorders, and cirrhosis state. Our results provide new evidence justifying the use of tenofovir or entecavir to prevent the evolution of CHB severity.
Authors
- Wan-Jung Wu (ORCID: https://orcid.org/0000-0002-3028-9146)
- Chih‐Lin Lin (ORCID: https://orcid.org/0000-0002-9890-7596)
- Ming‐Whei Yu (ORCID: https://orcid.org/0000-0002-8371-6236)
- Chun‐Jen Liu (ORCID: https://orcid.org/0000-0002-6202-0993)
- Wenjie Liu (ORCID: https://orcid.org/0000-0002-8044-5338)
- Jui‐Ting Hu (ORCID: https://orcid.org/0000-0002-7169-3911)
- Yi‐Wen Huang (ORCID: https://orcid.org/0000-0002-5196-7030)
Institutions
- Fu Jen Catholic University (TW)
- National Taiwan University (TW)
- Taipei City Hospital (TW)
- Cathay General Hospital (TW)
- National Taiwan University Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101511
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Taiwan University
- Health and Welfare Data Science Center
- National Science and Technology Council